Ads
related to: lupron injection drug test for prostate cancer in men- Contact Us
Contact our representatives
for product and reimbursement info.
- Case Studies
Review real case studies
with real patients.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
[2] [199] During continuous weekly intramuscular injections of CPA in men with prostate cancer, mean levels of CPA roughly doubled from 170 ng/mL (408 nmol/L) after the first injection to 310 ng/mL (744 nmol/L) after the fifth injection, and were projected to increase to 350 to 400 ng/mL (840–960 nmol/L) after around 8 to 12 injections. [122]
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
The risk of bone fractures in men with prostate cancer given androgen deprivation therapy has been estimated to be increased by 45%. [36] The incidence of osteoporosis increases in men with prostate cancer from 36% to 80% after 10 years of androgen deprivation therapy, and following that, it can be expected that all treated men will develop ...
The test had a 95% sensitivity among men who had a grade group 2 or greater cancer; this sensitivity improved to 99% in men with a grade group 3 or greater cancer. In practical terms, that means ...
Ads
related to: lupron injection drug test for prostate cancer in men